Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder

Cancer Detection and Prevention

Volumn 24, Issue 4, 2000, Pages 364-368

  Sawczuk, I S ^a   Bagiella, E ^a   Sawczuk, A T ^a   Yun, E J ^a  

^a Columbia University ^*  (United States)

Author keywords

Bladder neoplasms; Nuclear matrix proteins; Transitional cell carcinoma; Tumor markers

Indexed keywords

CARCINOMA CELL; CYTOSCOPY; IMMUNOASSAY; PATHOGENESIS; REFERENCE VALUE; RISK ASSESSMENT; TUMOR DIAGNOSIS; URINE; UROTHELIUM;

AGED; ANESTHETICS, LOCAL; BAYES THEOREM; BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CONSCIOUS SEDATION; CYSTOSCOPY; DECISION SUPPORT TECHNIQUES; FEMALE; HUMAN; IMMUNOASSAY; LIDOCAINE; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033785551     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Cancer statistics, 1999
2. Biology and the management of bladder cancer
3. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma
4. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer
5. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer
6. A multicellular trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer
7. Bayesian analysis of a protocol for sampling preserved tumor specimens
8. Progressive changes in the protein composition of the nuclear matrix during rat osteoblast differentiation
9. Nuclear matrix proteins reflect cell type of origin in cultured human cells
10. Utilization of nuclear matrix proteins for cancer diagnosis
11. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
12. Clinical evaluation of nuclear matrix protein 22 in urine as a novel marker for urothelial cancer
13. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
14. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer
15. Urinary NMP22 for the detection of recurrence of transitional cell carcinoma of the bladder: Experience on 137 patients